VIVUS (VVUS), Orexigen (OREX) Higher Ahead of PDUFA; Arena (ARNA) Lags
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
VIVUS (Nasdaq: VVUS) shares are about 0.9 percent higher ahead of the bell Tuesday, heading into its PDUFA date with the FDA for proposed obesity drug Qnexa.
Shares are been stuck in the $26 to $30 range over the last month, having popped last on June 27th following FDA approval of Arena's (Nasdaq: ARNA) Belviq (lorcaserin).
Also making a big move this morning is Orexigen (Nasdaq: OREX), which is still running tests on its Contrave obesity pill. Orexigen has been on a hot-streak, having closed higher 10 of the last 14 sessions.
Arena is in negative territory in early trading.
Shares are been stuck in the $26 to $30 range over the last month, having popped last on June 27th following FDA approval of Arena's (Nasdaq: ARNA) Belviq (lorcaserin).
Also making a big move this morning is Orexigen (Nasdaq: OREX), which is still running tests on its Contrave obesity pill. Orexigen has been on a hot-streak, having closed higher 10 of the last 14 sessions.
Arena is in negative territory in early trading.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Ionis Pharma's therapy to treat rare genetic disorder
- AbbVie's etentamig meets Phase 3 endpoints in multiple myeloma trial
- FDA approves first treatment for Alexander disease
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
